Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01133353
Other study ID # BVF-018-201
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date March 2011
Est. completion date December 2011

Study information

Verified date November 2019
Source Bausch Health Americas, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this clinical trial is to study the therapeutic effect of tetrabenazine MR in children with Tourette's Syndrome, as measured by the improvement in total tic score of the Yale Global Tic Severity Scale (YGTSS).


Description:

Tourette's Syndrome (TS) is typically diagnosed in early childhood (6-7 years) or before the age of 21 years and is characterized by chronic, intermittent motor and phonic tics. There is a body of evidence, mostly from the clinical experience data, suggesting the efficacy of tetrabenazine in TS patients with tics, including patients who were unresponsive to other treatment options. These publications consistently report the usefulness of tetrabenazine as an alternative to conventional neuroleptics for the treatment of TS.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender All
Age group 5 Years to 16 Years
Eligibility Inclusion Criteria:

Subjects must meet all of the following criteria:

1. Children aged 5 to up to 17 years

2. Subjects must be capable of providing informed consent or assent, if applicable, and parents/legal guardian must be capable of providing informed consent/permission and complying with study procedures

3. Subject and parents/legal guardian must be able to communicate effectively with Investigator and study coordinator

4. Diagnosed with Tourette's Syndrome, according to DSM-IV-TR and using K-SADS-PL to aid diagnosis, and requiring drug therapy

5. Total tic score = 22 as measured by YGTSS at screening and baseline

6. Total body weight = 15 kg (33 lbs.)

7. Tics are causing distress or impairment, as determined by parent/legal guardian or subject and by the Investigator, despite current treatment regimen

8. Able to swallow whole tablets without difficulty

9. Non-pregnant status:

- All female subjects must be non-pregnant (as demonstrated by negative serum ß-HCG test), non-breastfeeding, and must avoid pregnancy from at least 10 days before signing the informed consent/assent and up until 1 month after the end of the study by abstaining from sexual activity or using two (2) medically acceptable methods of contraception, such as: a non-hormonal IUD with spermicide, female condom with spermicide, contraceptive sponge with spermicide, an intravaginal system, diaphragm with spermicide, cervical cap with spermicide, a male sexual partner who agrees to use a male condom with spermicide, a sterile sexual partner.

- Male subjects must abstain from sexual activity from the time they sign the informed consent/assent and up until 1 month after the end of the study or use a condom with spermicide.

- For all females of child bearing potential, a serum pregnancy test result must be negative at Screening and urine pregnancy test must be negative at Baseline

Exclusion Criteria:

Subjects are not eligible if any of the following criteria are met:

1. Subjects with history or current major depressive disorder

2. Prior treatment with > 7 doses of tetrabenazine

3. Prior treatment with reserpine

4. Subjects with impaired renal function (defined as having a creatinine level of = 1.5 times the upper limit of age-appropriate normal value)

5. Subjects with current or any history of suicidal ideation

6. Participation in an investigational medication trial within the 3 months prior to the Screening visit, except for study BVF-018-102

7. Use of Botox® (botulinum toxin) within the 4 months prior to the Screening visit

8. Immediate families of site Investigators or sponsor employees

9. Excluding conditions related directly to the disease under study, subject has a history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.

10. Subjects with clinically important thyroid dysfunction requiring medication

11. Subjects with impaired hepatic function (defined as having SGOT/SGPT levels = 1.5 times the upper limit of age-appropriate normal values)

12. Subjects with a Children's Depression Rating Scale-Revised (CDRS-R) total score of > 65

13. Male subjects with QTc > 450 msec; female subjects with QTc > 470 msec based on Bazzett's correction formula

14. Organic brain disease, for example, traumatic brain injury residua or toxic delirium

15. Any subject at immediate risk of requiring hospitalization

16. Physical examination, electrocardiography, or laboratory values that are clinically important in the opinion of the Investigator

17. Autistic spectrum disorder

18. Schizophrenia

19. Other psychotic disorder

20. Subjects with Bipolar I Disorder

21. Subjects with one or more first-degree relatives with Bipolar I Disorder

22. Subjects who are unable to complete a washout period of 4 weeks for fluoxetine and 3 weeks for MAOIs, respectively, prior to Baseline visit and who require fluoxetine and MAOIs during the Treatment Period

23. Inability to washout of strong inhibitors or inducers of CYP2D6 within 7 days of the Baseline visit

24. Positive findings on urine drug screen at the Screening Visit

25. Allergies to tetrabenazine or its excipients

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tetrabenazine MR
Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks
Placebo
1 to 5 tablets once per day depending on weight for 12 weeks

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Bausch Health Americas, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Improvement in total tic score as measured by the Yale Global Tic Severity Score (YGTSS) Days 0 to 84
Secondary To evaluate the safety and tolerability of tetrabenazine using cognitive measures Days 0 and 84
Secondary To evaluate the safety and tolerability of tetrabenazine using an assessment of depression Days 0 to 84
Secondary To evaluate the safety and tolerability of tetrabenazine using an assessment of suicidality Days 0 to 91
Secondary To explore the therapeutic effects of tetrabenazine using the full YGTSS Days 0 to 84
Secondary To explore the therapeutic effects of tetrabenazine using the Patient Global Impression of Change scale (PGI-C) Days 0 to 84
Secondary To explore the therapeutic effects of tetrabenazine using the Clinical Global Impression of Severity scale (CGI-S) Days 0 to 84
See also
  Status Clinical Trial Phase
Recruiting NCT00965211 - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome N/A
Recruiting NCT00152750 - Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD Phase 4
Terminated NCT00226824 - Safety Study of Galantamine in Tic Disorders Phase 4
Completed NCT00241176 - Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Phase 4
Completed NCT01244633 - Ecopipam Treatment of Tourette Syndrome Phase 1/Phase 2
Recruiting NCT04805385 - Effects of Lactobacillus Plantarum PS128 in Patients With Tourette's Syndrome N/A
Completed NCT00026000 - Brain Activation in Vocal and Motor Tics N/A
Terminated NCT00001260 - Brain Tissue Collection for Neuropathological Studies
Completed NCT02102698 - Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years Phase 2
Withdrawn NCT02112253 - Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome Phase 1/Phase 2
Completed NCT02205918 - Brain-Behavior Interactions in Tic Suppression
Terminated NCT00282139 - Aripiprazole in the Treatment of Tourette's Syndrome N/A
Completed NCT03042507 - Psychosocial Intervention for Young Children With Chronic Tics N/A
Completed NCT01019343 - Physiological Investigations of Movement Disorders N/A
Completed NCT02619084 - Subthalamic Stimulation in Tourette's Syndrome Phase 2
Completed NCT00368433 - Hypersensitivity in Tourette Syndrome N/A
Withdrawn NCT01475383 - Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome Phase 2
Not yet recruiting NCT06361004 - Exploring DBS Efficacy in Treatment-refractory Tourette's Syndrome N/A
Completed NCT00139308 - High Frequency Stimulation of the GPi or Thalamus in Tourette's Syndrome Phase 1